NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
Clinical Trials
320 trialsNCT06285136 2024-02-29
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
Phase 2/3 Unknown
NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
NCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT06162325 2023-12-08
Venetoclax in Combination With Standard Induction and Consolidation Chemotherapy in Newly Diagnosed Young AML Patients
Peking Union Medical College Hospital
Unknown
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04257175 2023-11-28
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
Phase 2/3 Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT04964518 2023-10-25
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06084819 2023-10-16
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Chinese PLA General Hospital
Phase 2 Unknown
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT04888741 2023-09-28
MoTD
University of Birmingham
Phase 2 Unknown
NCT06008405 2023-09-06
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05982756 2023-08-09
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
Zhongnan Hospital
Phase 1 Unknown
NCT03867682 2023-08-04
Venetoclax and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
Phase 1/2 Unknown
NCT05226468 2023-07-27
An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
New Epsilon Innovation Limited
Phase 1 Unknown
NCT05951855 2023-07-19
Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05949762 2023-07-18
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
The Second Affiliated Hospital of Kunming Medical University
Phase 1/2 Unknown
NCT04923919 2023-07-13
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT05919199 2023-06-26
FDG-PETAML
First Affiliated Hospital of Jinan University
Unknown
NCT05264883 2023-05-30
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT05140811 2023-05-24
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1/2 Unknown
NCT05471323 2023-05-19
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Unknown
NCT04471064 2023-05-18
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Phase 1 Unknown
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05823714 2023-04-21
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05697510 2023-04-06
SILTUXILAM
Nantes University Hospital
Phase 1 Unknown
NCT05503355 2023-04-04
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
BioSight Ltd.
Phase 1/2 Unknown
NCT05791890 2023-03-30
GilteRInf
University of Rome Tor Vergata
Unknown
NCT02931942 2023-03-16
Changing Over Time of Ascorbic Acid After Chemotherapy
Maastricht University Medical Center
Unknown
NCT03846362 2023-03-16
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Unknown
NCT05448599 2023-03-15
A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT04749355 2023-03-09
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
BioSight Ltd.
Phase 2 Unknown
NCT05312112 2023-03-02
Real World Outcomes Using Novel Agents for AML in the UK
Guy's and St Thomas' NHS Foundation Trust
Unknown
NCT05744440 2023-02-27
Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT
Xuzhou Medical University
Phase EARLY_PHASE1 Unknown
NCT04669067 2023-02-17
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT05731219 2023-02-16
UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT02172872 2023-02-15
"InDACtion" vs "3+7" Induction in AML
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT05722171 2023-02-10
Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03533816 2023-02-08
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
University of Kansas Medical Center
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown